September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
The role of aldose reductase in the development of posterior capsular opacification
Author Affiliations & Notes
  • Leonid Zukin
    Ophthalmology, University of Colorado, Greenwood Village, Colorado, United States
  • Michelle Pedler
    Ophthalmology, University of Colorado, Greenwood Village, Colorado, United States
  • Biehuoy Shieh
    Ophthalmology, University of Colorado, Greenwood Village, Colorado, United States
  • J Mark Petrash
    Ophthalmology, University of Colorado, Greenwood Village, Colorado, United States
  • Footnotes
    Commercial Relationships   Leonid Zukin, None; Michelle Pedler, None; Biehuoy Shieh, None; J Petrash, None
  • Footnotes
    Support  NIH Grants EY021455 and EY005856
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Leonid Zukin, Michelle Pedler, Biehuoy Shieh, J Mark Petrash; The role of aldose reductase in the development of posterior capsular opacification. Invest. Ophthalmol. Vis. Sci. 2016;57(12):No Pagination Specified.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Cataract removal is one of the most common surgeries in the world. Approximately one-fifth of cataract patients will develop a postoperative condition known as posterior capsular opacification (PCO), whereby residual cells in the lens capsule proliferate and obstruct the visual axis. Recent studies have demonstrated that PCO biomarkers can be suppressed through inhibition of aldose reductase (AR), a protein involved with TGFβ-mediated signaling in lens epithelial cells. We hypothesize that inhibition of AR in a mouse model of cataract surgery will prevent the induction of PCO and associated biomarkers, including alpha smooth muscle actin (α-SMA), vimentin (VIM), and fibronectin (FN).

Methods : Extracapsular lens extraction was performed on one eye of wild-type C57BL/6, AR-transgenic, and AR knockout mice. Capsules were harvested 5 days post-operatively and PCO biomarker levels, measured by quantitative polymerase chain reaction (q-PCR), were compared between operated and non-operated eyes. In a separate experiment, whole eyes were harvested at 3 and 5 days post-operatively, sectioned (10 μm), and stained with DAPI and α-SMA fluorescent antibodies. To examine pharmacological AR inhibition, analogous surgical procedures were performed on the mice along with 10 mg/kg bid intraperitoneal injections with Sorbinil for 5 days, followed by q-PCR quantification of PCO biomarkers.

Results : As measured by qPCR, genetic knockout of AR suppressed post-operative PCO biomarkers by 66%, 27%, 79% for α-SMA, VIM, and FN, respectively. In contrast, AR overexpression greatly enhanced post-operative markers as evidenced by increases of 430%, 266%, and 359% for α-SMA, VIM, and FN, respectively. Pharmacological AR inhibition with Sorbinil recapitulated these results, with significant biomarker decreases in wild-type (86.99%, 69.95%, and 88.79% decrease in α-SMA, VIM, and FN, respectively) and AR-Tg mice (46.93%, 28.73%, and 43.99% decrease in α-SMA, VIM, and FN, respectively). Immunofluorescent imaging of α-SMA demonstrated development of the aberrant fibrotic process in the different strains.

Conclusions : This study validates the important role of AR in the development of PCO in vivo and presents a promising avenue for further research into the prevention of PCO through AR inhibition.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×